Marcelo de Gomes
Universidade Federal do Pampa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marcelo de Gomes.
Progress in Neuro-psychopharmacology & Biological Psychiatry | 2013
Leandro Cattelan Souza; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Lucian Del Fabbro; Carlos Borges Filho; Silvana Peterini Boeira; Cristiano R. Jesse
The present study investigated a possible antidepressant-like activity of hesperidin using two predictive tests for antidepressant effect in mice: the forced swimming test (FST) and the tail suspension test (TST). Results demonstrated that hesperidin (0.1, 0.3 and 1 mg/kg, intraperitoneal, i.p.) decreased the immobility time in the FST and TST without affecting the locomotor activity in the open field test. The antidepressant-like effect of hesperidin (0.3 mg/kg) on the TST was prevented by the pretreatment of mice with p-chlorophenylalanine methyl ester (pCPA; 100 mg/kg, i.p., an inhibitor of serotonin synthesis) and WAY100635 (0.1 mg/kg, subcutaneous, s.c., a selective 5-HT(1A) receptor antagonist). Pretreatment of mice with prazosin (1 mg/kg, i.p., an α(1)-adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an α(2)-adrenoceptor antagonist), propranolol (2 mg/kg, i.p., a β-adrenoceptor antagonist), AMPT (100 mg/kg, i.p., an inhibitor of tyrosine hydroxylase), SCH23390 (0.05 mg/kg, s.c., a dopamine D(1) receptor antagonist), sulpiride (50 mg/kg, i.p., a dopamine D(2) receptor antagonist), ketanserin (1mg/kg, i.p., a 5-HT(2A/2C) receptor antagonist) or MDL72222 (1 mg/kg, i.p., a 5-HT(3) receptor antagonist) did not block the antidepressant-like effect of hesperidin (0.3 mg/kg, i.p.) in the TST. Administration of hesperidin (0.01 mg/kg, i.p.) and fluoxetine (1 mg/kg), at subeffective doses, produced an antidepressant-like effect in the TST. The antidepressant-like effect caused by hesperidin in mice in the TST was dependent on an interaction with the serotonergic 5-HT(1A) receptors. Taken together, these results suggest that hesperidin possesses antidepressant-like property and may be of interest source for therapeutic agent for the treatment of depressive disorders.
European Journal of Pharmacology | 2013
Carlos Borges Filho; Lucian Del Fabbro; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Leandro Cattelan Souza; Silvana Peterini Boeira; Cristiano R. Jesse
The opioid system has been implicated as a contributing factor for major depression and is thought to play a role in the mechanism of action of antidepressants. This study investigated the involvement of the opioid system in the antidepressant-like effect of hesperidin in the mouse forced swimming test. Our results demonstrate that hesperidin (0.1, 0.3 and 1 mg/kg; intraperitoneal) decreased the immobility time in the forced swimming test without affecting locomotor activity in the open field test. The antidepressant-like effect of hesperidin (0.3 mg/kg) in the forced swimming test was prevented by pretreating mice with naloxone (1 mg/kg, a nonselective opioid receptor antagonist) and 2-(3,4-dichlorophenyl)-Nmethyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl] acetamide (DIPPA (1 mg/kg), a selective κ-opioid receptor antagonist), but not with naloxone methiodide (1 mg/kg, a peripherally acting opioid receptor antagonist), naltrindole (3 mg/kg, a selective δ-opioid receptor antagonist), clocinnamox (1 mg/kg, a selective μ-opioid receptor antagonist) or caffeine (3 mg/kg, a nonselective adenosine receptor antagonist). In addition, a sub-effective dose of hesperidin (0.01 mg/kg) produced a synergistic antidepressant-like effect in the forced swimming test when combined with a sub-effective dose of morphine (1 mg/kg). The antidepressant-like effect of hesperidin in the forced swimming test on mice was dependent on its interaction with the κ-opioid receptor, but not with the δ-opioid, μ-opioid or adenosinergic receptors. Taken together, these results suggest that hesperidin possesses antidepressant-like properties and may be of interest as a therapeutic agent for the treatment of depressive disorders.
Pharmacology, Biochemistry and Behavior | 2012
Mariana Freire Barbieri Gerzson; Francine Novack Victoria; Cátia S. Radatz; Marcelo Gomes de Gomes; Silvana Peterini Boeira; Raquel G. Jacob; Diego Alves; Cristiano R. Jesse; Lucielli Savegnago
In this study, the antioxidant and antidepressant-like effects of α-(phenylselanyl) acetophenone (PSAP), an organoselenium compound, were investigated. To assess the in vitro antioxidant properties, PSAP was evaluated in four test systems (DPPH, ABTS, FRAP and inhibition of lipid peroxidation). PSAP (100-500 μM) showed potent antioxidant activity and protected against lipid peroxidation. Additionally, we investigated whether PSAP, when administered in mice (100, 200 and 400mg/kg, per oral, p.o.), could cause acute toxicity. Our results demonstrated that PSAP did not cause the death of any animal, significantly reduce body weight or cause any oxidative tissue stress following treatment. This study also evaluated the effect of PSAP (0.1-10 mg/kg, p.o) on mice in a forced swim test (FST) and tail suspension test (TST), assays that are predictive of depressant activity and motor activity in the open-field. PSAP (5-10 mg/kg) significantly reduced immobility time in the FST and TST without affecting motor activity. In addition, the antidepressant-like effect caused by PSAP (5m/kg, p.o) in mice during the TST was dependent on an interaction with the serotonergic system (5-HT(1A) receptors), but not with the noradrenergic, dopaminergic or adenosinergic system. Together, these results suggest that PSAP possesses antioxidant and antidepressant-like properties and may be of interest as a therapeutic agent for the treatment of depressive disorders.
Chemico-Biological Interactions | 2015
Silvana Peterini Boeira; Vinícius Rafael Funck; Carlos Borges Filho; Lucian Del Fabbro; Marcelo Gomes de Gomes; Franciele Donato; Luiz Fernando Freire Royes; Mauro Schneider Oliveira; Cristiano R. Jesse; Ana Flávia Furian
Male mice received lycopene for 10 days before a single oral administration of zearalenone (ZEA). After 48 h testes and blood were collected. Mice treated with lycopene/ZEA exhibited amelioration of the hematological changes. Lycopene prevented the reduction in the number and motility of spermatozoa and testosterone levels, indicating a protective effect in the testicular damage induced by ZEA. Lycopene was also effective in protecting against the decrease in glutathione-S-transferase, glutathione peroxidase, glutathione reductase and δ-aminolevulinic acid dehydratase activities caused by ZEA in the testes. Exposure of animals to ZEA induced modification of antioxidant and inflammatory status with increase of reduced glutathione (GSH) levels and increase of the oxidized glutathione, interleukins 1β, 2, 6, 10, tumor necrosis factor-α and bilirubin levels. Lycopene prevented ZEA-induced changes in GSH levels and inhibited the processes of inflammation, reducing the damage induced by ZEA. Altogether, our results indicate that lycopene was able to prevent ZEA-induced damage in the mice.
Pharmacology, Biochemistry and Behavior | 2015
Leandro Cattelan Souza; Michelle S. Antunes; Carlos Borges Filho; Lucian Del Fabbro; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Franciele Donato; Marina Prigol; Silvana Peterini Boeira; Cristiano R. Jesse
In this study, the effect of Chrysin (5,7-dihydroxyflavone), an important member of the flavonoid family, on memory impairment, oxidative stress and BDNF reduction generated by aging in mice were investigated. Young and aged mice were treated daily per 60days with Chrysin (1 and 10mg/kg; per oral, p.o.) or veichle (10ml/kg; p.o.). Mice were trained and tested in Morris Water Maze task. After the behavioural test, the levels of reactive species (RS), the activity of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx), as well as the activity of Na(+), K(+)-ATPase and the levels of brain-derived neurotrophic factor (BDNF) were determined in the prefrontal cortex (PFC) and hippocampus (HC) of mice. Results demonstrated that the age-related memory decline was partially protected by Chrysin at a dose of 1mg/kg, and normalized at the dose of 10mg/kg (p<0.001). Treatment with Chrysin significantly attenuated the increase of RS levels and the inhibition of SOD, CAT and GPx activities of aged mice. Inhibition of Na(+), K(+)-ATPase activity in PFC and HP of aged mice was also attenuated by Chrysin treatment. Moreover, Chrysin marked mitigated the decrease of BDNF levels in the PFC and HC of aged mice. These results demonstrated that flavonoid Chrysin, an antioxidant compound, was able to prevent age-associated memory probably by their free radical scavenger action and modulation of BDNF production. Thus, this study indicates that Chrysin may represent a new pharmacological approach to alleviate the age-related declines during normal age, acting as an anti-aging agent.
Life Sciences | 2013
Franciele Donato; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Natália Seus; Diego Alves; Cristiano R. Jesse; Lucielli Savegnago
AIMS The study investigated the antidepressant-like effect and acute toxicity of 4-phenyl-1-(phenylselanylmethyl)-1,2,3-triazole (Se-TZ), an organoselenium-containing heterocycle compound in mice. MAIN METHODS The antidepressant-like effect of Se-TZ (1-50mg/kg) and its mechanism of action, was analyzed in the tail suspension test (TST) in male C57BL/6J mice. Additionally, the levels of the monoamines and their metabolites in cerebral cortex and hippocampus were analyzed by high-performance liquid chromatography. To investigate the potential acute toxicity caused by Se-TZ, the mice received a single oral dose of Se-TZ (1-50mg/kg), and after 72h were performed the assays. KEY FINDINGS The Se-TZ (5-50mg/kg) significantly reduced immobility time in TST without altering locomotor and exploratory activities. The antidepressant-like effect of Se-TZ (25mg/kg) in the TST was prevented by pre-treatment of mice with SCH23390, sulpiride and methysergide, but not with prazosin, yohimbine and propranolol. Se-TZ, increased monoamine neurotransmitters dopamine and serotonin levels in the cerebral cortex and hippocampus, whereas norepinephrine turnover was not changed. This study also demonstrated that the Se-TZ, did not cause the acute toxicity in biochemical markers hepatic and renal investigated. The results evidenced that exposure to Se-TZ caused a significant increase in the catalase (CAT) activity in the cerebral cortex and hippocampus, however the glutathione S-transferase (GST) activity increased only in the cerebral cortex. SIGNIFICANCE These results suggest that Se-TZ demonstrated antidepressant-like effect, mediated via the central dopaminergic and serotoninergic neurotransmitter systems which may be of interest as a therapeutic agent for the treatment of depressive disorders.
European Journal of Pharmacology | 2016
Carlos Borges Filho; Cristiano R. Jesse; Franciele Donato; Lucian Del Fabbro; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Leandro Cattelan Souza; Renata Giacomeli; Michelle S. Antunes; Cristiane Luchese; Silvane Souza Roman; Silvana Peterini Boeira
Chrysin is a flavonoid which is found in bee propolis, honey and various plants. Antidepressant-like effect of chrysin in chronically stressed mice was previously demonstrated by our group. Conversely, neurochemical factors associated with this effect require further investigations. Thus, we investigated the possible involvement of pro-inflammatory cytokines, kynurenine pathway (KP), 5-hydroxytryptamine (5-HT) metabolism and caspases activities in the effect of chrysin in mice exposed to unpredictable chronic stress (UCS). UCS applied for 28 days induced a depressive-like behavior, characterized by decrease in the time of grooming in the splash test and by increase in the immobility time in the tail suspension test. Oral treatment with chrysin (5 or 20mg/kg, 28 days), similarly to fluoxetine (10mg/kg, positive control), culminated in the prevention of these alterations. UCS elevated plasma levels of corticotropin-releasing hormone and adrenocorticotropic hormone, as well the tumor necrosis factor-α, interleukin-1β, interleukin-6 and kynurenine levels in the prefrontal cortex (PFC) and hippocampus (HP). UCS induced the decrease in the 5-HT levels in the HP and the increase in the indoleamine-2,3-dioxygenase, caspase 3 and 9 activities in the PFC and HP. Treatment with chrysin, similarly to fluoxetine, promoted the attenuation of these alterations occasioned by UCS. These results corroborated with the antidepressant potential of chrysin in the treatment of psychiatric diseases. Furthermore, this work indicated the association of pro-inflammatory cytokines synthesis, KP, 5-HT metabolism and caspases activities with the action exercised by chrysin in mice exposed to UCS.
Hormones and Behavior | 2015
Michelle S. Antunes; Jossana Rodrigues Ruff; Dieniffer de Oliveira Espinosa; Manuela Bastos Piegas; Maicon Lenon Otenio de Brito; Kellen Rocha; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Leandro Cattelan Souza; Franciele Donato; Silvana Peterini Boeira; Cristiano R. Jesse
Depression is one of the most common mental disorders and a primary cause of disability. To better treat patients suffering this illness, elucidation of the underlying psychopathological and neurobiological mechanisms is urgently needed. Based on the above-mentioned evidence, we sought to investigate the effects of neuropeptide Y (NPY) treatment in tricyclic antidepressant treatment-resistant depression induced by adrenocorticotropic hormone (ACTH) administration. Mice were treated with NPY (5.84, 11.7 or 23.4mmol/μl) intracerebroventricularly (i.c.v.) for one or five days. The levels of serum corticosterone, tryptophan (TRP), kynurenine (KYN), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and indoleamine 2,3-dioxygenase (IDO) activity in the hippocampus were analyzed. The behavioral parameters (depressive-like and locomotor activity) were also verified. This study demonstrated that ACTH administration increased serum corticosterone levels, KYN, 5-HIAA levels, IDO activity (hippocampus), immobility in the forced swimming test (FST) and the latency to feed in the novelty suppressed feeding test (NSFT). In addition, ACTH administration decreased the BDNF and NGF levels in the hippocampus of mice. NPY treatment was effective in preventing these hormonal, neurochemical and behavioral alterations. It is suggested that the main target of NPY is the modulation of corticosterone and neuronal plasticity protein levels, which may be closely linked with pharmacological action in a model of tricyclic antidepressant treatment-resistant depression. Thus, this study demonstrated a protective effect of NPY on the alterations induced by ACTH administration in mice, indicating that it could be useful as a therapy for the treatment of tricyclic antidepressant treatment-resistant depression.
Behavioural Brain Research | 2017
Leandro Cattelan Souza; Cristiano R. Jesse; Lucian Del Fabbro; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Carlos Borges Filho; Cristiane Luchese; Albanin Aparecida Mielniczki Pereira; Silvana Peterini Boeira
HighlightsA&bgr;1‐42‐induced behavioural and neurobiological deficits in mice.Brain IDO activation contributes to behavioural disturbances induced by A&bgr;1‐42.Swimming prevents behavioural disturbances induced by A&bgr;1‐42.Swimming inhibited neuroinflammation and neurotrophic deficiency elicited by A&bgr;1‐42.Swimming blocked KYN pathway dysregulation in brain of A&bgr;1‐42‐treated mice. Abstract Emerging evidence indicates that the activation of indoleamine‐2,3‐dioxygenase (IDO), a first and rate‐limiting enzyme in the kynurenine (KYN) pathway, is involved in amyloid‐beta (A&bgr;1‐42)‐neurotoxicity and Alzheimer’s disease (AD) pathogenesis. Physical exercise has been considered an effective intervention in AD, attenuating or limiting their progression. Nevertheless, the neurobiological mechanisms underlying the neuroprotective effects of exercise have not yet been fully elucidated. In present study, we investigated the protective effect of an 8‐week swimming training (ST) exercise on cognitive and non‐cognitive functions and its role in modulating biomarkers of KYN pathway, before an intracerebroventricular (i.c.v.) injection of A&bgr;1‐42 (400 pmol/animal; 3 &mgr;l/site) peptide in mice. Our results demonstrated that ST was effective in preventing the following behavioural disturbances caused by A&bgr;1‐42 injection: memory impairment in the object recognition test and depressive/anxiety‐like behaviour in the tail suspension test and elevated plus‐maze test, respectively. ST abrogated the neuroinflammatory response and neurotrophic deficiency in the prefrontal cortex and hippocampus induced by A&bgr;1‐42. Also, A&bgr;1‐42 increased IDO activity, KYN and tryptophan (TRP) levels and KYN:TRP ratio in the prefrontal cortex and hippocampus − alterations that were blocked by ST. It can be concluded that ST prevented behavioural and neurobiological deficits induced by A&bgr;1‐42, and suggest that these neuroprotective effects are likely to involve the inhibition of inflammation/IDO activation and up‐regulation of neurotrophic factors in brain of mice. Thus, it is possible that physical exercise can be used as a non‐pharmacological approach to alleviates both cognitive and non‐cognitive symptoms of AD.
Molecular and Cellular Neuroscience | 2018
Leandro Cattelan Souza; Cristiano R. Jesse; Lucian Del Fabbro; Marcelo Gomes de Gomes; Nathalie Savedra Gomes; Carlos Borges Filho; André Tiago Rossito Goes; Ethel A. Wilhelm; Cristiane Luchese; Silvane Souza Roman; Silvana Peterini Boeira
&NA; An increasing body of evidence indicates that the activation of indoleamine‐2,3‐dyoxigenase (IDO), a first and rate‐limiting enzyme in the kynurenine (KYN) pathway, is involved in A&bgr;1–42‐neurotoxicity and AD pathogenesis. We have reported for the first time that brain IDO activation is related to A&bgr;1–42 exposure in young mice. Because aging is characterized by a brain dyshomeostasis and because it remains the most dominant risk factor for AD, the purpose of this study was to determine whether aging is associated with a higher sensitivity to behavioural and neurochemical alterations elicited by an intracerebroventricular (i.c.v.) injection of A&bgr;1–42 (400 pmol/mice), and whether KYN pathway is involved in these effects. We confirmed that aged mice displayed higher cognitive deficit in the object recognition test and higher anxiety‐like behaviour in the elevated plus‐maze and open field tests after the A&bgr;1–42 administration. Aged mice also responded to A&bgr;1–42 with a higher deficiency of brain‐derived neurotrophic factor, glutathione levels and total radical‐trapping antioxidant capacity, a higher IDO activity, and a higher KYN and KYN/tryptophan ratio in the prefrontal cortex and hippocampus. These effects of A&bgr;1–42 were associated with a higher proinflammatory status, as measured by higher levels of interleukin‐6, lower levels of interleukin‐10 and higher expression of glial fibrillary acidic protein (GFAP) and allograft inflammatory factor 1 (Iba1) in the brain of aged mice. These results represent primary evidence suggesting that age‐associated inflammatory signature and down‐regulation of neuroprotectants in the brain render aged mice more vulnerable to A&bgr;1–42‐induced memory loss, anxiety symptoms and KYN pathway dysregulation. HighlightsIndoleamine‐2,3‐dioxigenase mediates behavioural disturbances induced by A&bgr;1–42.Aging exacerbates A&bgr;1–42‐induced cognitive and anxiety deficits.Aging aggravates A&bgr;1–42‐mediated neuroinflammation.Aging aggravates BDNF and antioxidant deficiency elicited by A&bgr;1–42.Aging further increase KYN dysregulation in brain of A&bgr;1–42‐treated mice.